[{"orgOrder":0,"company":"Epicrispr Biotechnologies","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series B Financing","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epicrispr Biotechnologies","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.070000000000000007,"dosageForm":"Intravenous Injection","sponsorNew":"Epicrispr Biotechnologies \/ Ally Bridge Group","highestDevelopmentStatusID":"5","companyTruncated":"Epicrispr Biotechnologies \/ Ally Bridge Group"},{"orgOrder":0,"company":"Epicrispr Biotechnologies","sponsor":"Springbok Analytics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Epicrispr Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Epicrispr Biotechnologies \/ Springbok Analytics","highestDevelopmentStatusID":"7","companyTruncated":"Epicrispr Biotechnologies \/ Springbok Analytics"},{"orgOrder":0,"company":"Epicrispr Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Epicrispr Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Epicrispr Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Epicrispr Biotechnologies \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Epicrispr Biotechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : The partnership aims to advance the clinical development of EPI-321, which is being evaluated in ther early-stage clinical trial studies for the treatment of FSHD.

                          Product Name : EPI-321

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 23, 2025

                          Lead Product(s) : EPI-321

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Springbok Analytics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : EPI-321, a first-in-class epigenetic therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease.

                          Product Name : EPI-321

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          April 03, 2025

                          Lead Product(s) : EPI-321

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : The financing aims to fund the clinical development of lead program, EPI-321. It is being evaluated for the treatment of facioscapulohumeral muscular dystrophy.

                          Product Name : EPI-321

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 26, 2025

                          Lead Product(s) : EPI-321

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : IND Enabling

                          Sponsor : Ally Bridge Group

                          Deal Size : $68.0 million

                          Deal Type : Series B Financing

                          blank